Our in vivo results showed that CD2‐deficient CTLs significantly accelerated tumor growth and metastasis, as evidenced by increased subcutaneous tumor volume, enlarged brain metastatic lesions, elevated Ki67‐positive proliferating cells, and reduced Caspase‐3 expression, indicating enhanced tumor proliferation and reduced apoptosis. This evidence concerns the gene CD2 and neoplasm.